Bristol Myers Squibb (BMY) Wins FDA OK to Expand CAMZYOS to Pediatric oHCM
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its drug CAMZYOS (mavacamten). The approval allows the drug to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in both adult and pediatric patients weighing at least 30 kg.
Bristol Myers Squibb said the FDA approved an expanded indication for CAMZYOS (mavacamten) to treat symptomatic obstructive HCM in adults and pediatric patients weighing ≥30 kg.Material DetailsContext by AI AnalystThis is a late-stage regulatory expansion that builds on CAMZYOS’s established adult…